%0 Journal Article
%A Klein, Eva-Maria
%A Tichy, Diana
%A Salwender, Hans J
%A Mai, Elias K
%A Duerig, Jan
%A Weisel, Katja C
%A Benner, Axel
%A Bertsch, Uta
%A Akhavanpoor, Mabast
%A Besemer, Britta
%A Munder, Markus
%A Lindemann, Hans-Walter
%A Hose, Dirk
%A Seckinger, Anja
%A Luntz, Steffen
%A Jauch, Anna
%A Elmaagacli, Ahmet
%A Fuhrmann, Stephan
%A Brossart, Peter
%A Goerner, Martin
%A Bernhard, Helga
%A Raab, Marc S
%A Blau, Igor W
%A Haenel, Mathias
%A Scheid, Christof
%A Goldschmidt, Hartmut
%A On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg
%T Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
%J Cancers
%V 13
%N 19
%@ 2072-6694
%C Basel
%I MDPI
%M DKFZ-2021-02258
%P 4856
%D 2021
%X We investigated the prognostic impact of time-dependent serum free light chain ratio (FLCr) normalization in 590 patients with secretory multiple myeloma (MM) during first-line treatment within the German-Speaking Myeloma Multicenter Group MM5 trial. Serum free light chains (sFLC) were assessed by the Freelite test at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow up within two years after the start of maintenance. The proportion of patients with a normal or normalized FLCr increased from 3.6
%K immune reconstitution (Other)
%K multiple myeloma (Other)
%K prognostic factors (Other)
%K serum free light chain ratio normalization (Other)
%K time-dependent analysis (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34638344
%R 10.3390/cancers13194856
%U https://inrepo02.dkfz.de/record/177028